NASH and Systemic Complications: From Basic to Clinical Research

S. Baumgartner; R. Shiri-Sverdlov

doi:10.3390/biomedicines9121913

NASH and Systemic Complications: From Basic to Clinical Research

S. Baumgartner^*, R. Shiri-Sverdlov^*

^*Corresponding author for this work

Research output: Contribution to journal › Editorial › Academic › peer-review

Abstract

Nonalcoholic fatty liver disease (NAFLD) is known as the hepatic manifestation of the metabolic syndrome, and while most patients develop simple steatosis, up to one-third can develop nonalcoholic steatohepatitis (NASH) [...]

Original language	English
Article number	1913
Number of pages	4
Journal	Biomedicines
Volume	9
Issue number	12
DOIs	https://doi.org/10.3390/biomedicines9121913
Publication status	Published - 1 Dec 2021

Access to Document

10.3390/biomedicines9121913Licence: CC BY

Cite this

@article{cbf0f94728e04cb7b593c874173d4478,

title = "NASH and Systemic Complications: From Basic to Clinical Research",

abstract = "Nonalcoholic fatty liver disease (NAFLD) is known as the hepatic manifestation of the metabolic syndrome, and while most patients develop simple steatosis, up to one-third can develop nonalcoholic steatohepatitis (NASH) [...]",

author = "S. Baumgartner and R. Shiri-Sverdlov",

year = "2021",

month = dec,

day = "1",

doi = "10.3390/biomedicines9121913",

language = "English",

volume = "9",

journal = "Biomedicines",

issn = "2227-9059",

publisher = "MDPI AG",

number = "12",

}

TY - JOUR

T1 - NASH and Systemic Complications: From Basic to Clinical Research

AU - Baumgartner, S.

AU - Shiri-Sverdlov, R.

PY - 2021/12/1

Y1 - 2021/12/1

N2 - Nonalcoholic fatty liver disease (NAFLD) is known as the hepatic manifestation of the metabolic syndrome, and while most patients develop simple steatosis, up to one-third can develop nonalcoholic steatohepatitis (NASH) [...]

AB - Nonalcoholic fatty liver disease (NAFLD) is known as the hepatic manifestation of the metabolic syndrome, and while most patients develop simple steatosis, up to one-third can develop nonalcoholic steatohepatitis (NASH) [...]

U2 - 10.3390/biomedicines9121913

DO - 10.3390/biomedicines9121913

M3 - Editorial

C2 - 34944726

SN - 2227-9059

VL - 9

JO - Biomedicines

JF - Biomedicines

IS - 12

M1 - 1913

ER -